Interestingly, our data support a compensatory role for Nrf2, a major regulator of cellular antioxidant defense, which might correlate with enhanced levels and activity of GCL (and of its catalytic subunit, GCLc), an enzyme involved in GSH synthesis, in peripheral cells from both T2D and T2D-PDT patients. Here, NFE2L2 is linked to type 2 diabetes mellitus.